Lexicon Pharmaceuticals (LXRX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

LXRX Lexicon Pharmaceuticals

Watchlist

0.805
-0.015-1.87%

Close Nov 27 16:00 ET

0.819
+0.014+1.69%

Post 18:24 ET

290.97MMarket Cap-1087P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Cuts Target Price to $1.2
Moomoo NewsNov 27 16:31 ET · Ratings
Analysts Conflicted on These Healthcare Names: Lexicon Pharmaceuticals (LXRX), Halozyme (HALO) and Crinetics Pharmaceuticals (CRNX)
TipRanksNov 27 00:42 ET · Ratings
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $4
Moomoo NewsNov 26 10:31 ET · Ratings
Lexicon Pharmaceuticals: Strategic Focus on Promising Pipeline Amid Clinical Progress and Restructuring
TipRanksNov 26 09:45 ET
Express News | Lexicon Pharmaceuticals Inc - Top-Line Data From Progress Study Expected in Q1 2025
ReutersNov 26 08:00 ET
Express News | Lexicon Announces Completion of Enrollment in Phase 2B Progress Study of Lx9211 in Diabetic Peripheral Neuropathic Pain (Dpnp)
ReutersNov 26 08:00 ET

Comments

Clintzilla

Nov 26 18:28

$Lexicon Pharmaceuticals (LXRX.US)$ interesting

Trytosaveabit

Nov 22 06:49

Update

$Lexicon Pharmaceuticals (LXRX.US)$ Lexicon Pharmaceuticals Says Company Has Made Strategic Decision To Eliminate Its Commercial Operations And Rationalize Resources Across All Functions In Order To Preserve Cash And Focus Its Resources On Advancing Promising Clinical Development Pipeline Following Regulatory Update From FDA; Efforts Expected To Reduce 2025 Operating Costs By $100M
This decision follows the receipt of a "deficiencies preclude discussion" letter from the U.S. Food and Drug A...